Low risk — use of or exposure to this product is not likely to cause adverse health consequences.
Meclizine hydrochloride tablets USP Recalled by Jubilant Cadista Pharmaceuticals, Inc. Due to Marketed without an approved NDA/ANDA: Bottles were released...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Jubilant Cadista Pharmaceuticals, Inc. directly.
Affected Products
Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06
Quantity: 744 bottles
Why Was This Recalled?
Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About Jubilant Cadista Pharmaceuticals, Inc.
Jubilant Cadista Pharmaceuticals, Inc. has 29 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report